Firefly Luciferase BCMA Raji Cell Line

Firefly Luciferase BCMA Raji Cell Line is a Raji cell line constitutively expressing full length human BCMA (B-cell maturation antigen, also known as CD269, NM_ 001192) and firefly luciferase. This cell line has been validated by flow cytometry and for luciferase activity. B-Cell Maturation Antigen (BCMA), also known as CD269, is a cell surface receptor of the TNF receptor superfamily that recognizes B-Cell Activating Factor (BAFF). BCMA is preferentially expressed on mature B-lymphocytes and Multiple Myeloma (MM) cells. BCMA is a highly attractive target antigen for immunotherapy, not only because of its restricted expression in nonmalignant tissue, but also due to its almost universal expression on MM cells. Preclinical studies using CAR (Chimeric Antigen Receptor) T cells targeting BCMA have demonstrated anti-MM activity, and in 2017, the FDA granted BCMA CAR-T Cell immunotherapy breakthrough designation in treating Multiple Myeloma.